Phase III Trial of Carboplatin and Paclitaxel With or Without Sorafenib in Metastatic Melanoma

2012220 citationsJournal Articlebronze Open Access

Authors

Keith T. Flaherty

Sandra J. Lee

Philip D. Leming · Oncology Hematology Care

John M. Kirkwood

Abstract

Sorafenib does not improve OS when given in combination with CP for chemotherapy-naive patients with metastatic melanoma. This study establishes benchmark end points for the CP regimen in first-line therapy of metastatic melanoma.

Topics & Keywords

Melanoma and MAPK Pathways Cutaneous Melanoma Detection and Management Colorectal Cancer Treatments and Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 31, Issue 3, pp. 373-379

DOI: 10.1200/jco.2012.42.1529

Field-Weighted Citation Impact: 9.93